Rita de Cássia Collaço, Maxime Lammens, Carley Blevins, Kristen Rodgers, Andrei Gurau, Suguru Yamauchi, Christine Kim, Jeannine Forrester, Edward Liu, Jinny Ha, Yuping Mei, Corrine Boehm, Elizabeth Wohler, Nara Sobreira, Peter C Rowe, David Valle, Malcolm V Brock, Frank Bosmans
PURPOSE: Guanfacine is an α2A -adrenergic receptor agonist, FDA-approved to treat attention-deficit hyperactivity disorder and high blood pressure, typically as an extended-release formulation up to 7 mg/day. In our dysautonomia clinic, we observed that off-label use of short-acting guanfacine at 1 mg/day facilitated symptom relief in two families with multiple members presenting with severe generalized anxiety. We also noted anecdotal improvements in associated dysautonomia symptoms such as hyperhidrosis, cognitive impairment, and palpitations...
December 8, 2023: Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society